• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merck’s efficiency program to make cuts across all businesses and regions

Merck’s efficiency program to make cuts across all businesses and regions

February 27, 2012
CenterWatch Staff

Merck's executive board has presented initial plans for an efficiency program spanning all businesses as part of the company's comprehensive transformation program announced last year.

The efficiency program consists of two phases: In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and develop a long-term growth strategy. In the second phase, the focus will be on exploiting new growth opportunities.

"Over the next two years Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model,” said Karl-Ludwig Kley, chairman of the executive board. “While it is regrettable, our preliminary analysis has shown that the overall purpose of our transformation program and the expected measures to realize it may lead to workforce reductions across all businesses and regions."

Merck will consult with employee representatives in different countries with the intention of seeking socially acceptable solutions where they are possible. Until the consultations are further along, no detailed cost or headcount reduction plans will be announced.

At the beginning of 2012, Merck started the implementation of a new leadership organization that defines the relationship of businesses, group functions and country organizations. The objective is to streamline the organizational structure to be leaner and easier to navigate and to speed up decision-making processes. The realignment will continue in parallel with and support the efficiency program.

In the second phase of the program, Merck will tap areas for future growth based on broader industry and macroeconomic trends. Initial work to explore these growth opportunities has already begun, and Merck will further drive the development of its long-term growth strategy over the next two years.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing